MedTrace Logo

Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients

NCT02413801 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2025-03-06

No results posted yet for this study

Summary

The events that underlie the conversion from Psoriasis to Psoriatic Arthritis (PsA) are not well understood. This conversion occurs 30% of the time within the first 10 years of psoriasis diagnosis. PsA patients have about a 50% chance of developing joint damage within the first 2 years of disease. A biomarker that identifies subclinical joint inflammation in psoriasis patients would allow for a diagnostic tool to allow for earlier intervention in psoriasis patients and provide a better understanding of the underlying molecular pathogenesis that may lead to development of new therapeutic targets in PsA.

Conditions

Sponsors & Collaborators

  • Rheumatology Research Foundation

    collaborator OTHER

  • University of Rochester

    lead OTHER

Principal Investigators

  • Christopher Ritchlin, MD/MPH · University of Rochester

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-19
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02413801 on ClinicalTrials.gov